dc.contributor.author | Zaman, Mehfuz | |
dc.contributor.author | Chandrudu, Saranya | |
dc.contributor.author | Giddam, Ashwini K | |
dc.contributor.author | Reiman, Jennifer | |
dc.contributor.author | Skwarczynski, Mariusz | |
dc.contributor.author | McPhun, Virginia | |
dc.contributor.author | Moyle, Peter M | |
dc.contributor.author | Batzloff, Michael R | |
dc.contributor.author | Good, Michael F | |
dc.contributor.author | Toth, Istvan | |
dc.date.accessioned | 2017-05-03T12:53:54Z | |
dc.date.available | 2017-05-03T12:53:54Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 1743-5889 | |
dc.identifier.doi | 10.2217/nnm.14.190 | |
dc.identifier.uri | http://hdl.handle.net/10072/67262 | |
dc.description.abstract | Aim: Utilize lipopeptide vaccine delivery system to develop a vaccine candidate against Group A Streptococcus. Materials & methods: Lipopeptides synthesized by solid-phase peptide synthesis-bearing carboxyl (C)-terminal and amino (N)-terminal Group A Streptococcus peptide epitopes. Nanoparticles formed were evaluated in vivo. Results: Immune responses were induced in mice without additional adjuvant. We demonstrated for the first time that incorporation of the C-terminal epitope significantly enhanced the N-terminal epitope-specific antibody response and correlated with forming smaller nanoparticles. Antigen-presenting cells had increased uptake and maturation by smaller, more immunogenic nanoparticles. Antibodies raised by vaccination recognized isolates. Conclusion: Demonstrated the lipopeptidic nanoparticles to induce an immune response which can be influenced by the combined effect of epitope choice and size. | |
dc.description.peerreviewed | Yes | |
dc.description.publicationstatus | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Future Medicine | |
dc.publisher.place | United Kingdom | |
dc.relation.ispartofstudentpublication | N | |
dc.relation.ispartofpagefrom | 2613 | |
dc.relation.ispartofpageto | 2624 | |
dc.relation.ispartofissue | 17 | |
dc.relation.ispartofjournal | Nanomedicine | |
dc.relation.ispartofvolume | 9 | |
dc.rights.retention | Y | |
dc.subject.fieldofresearch | Proteins and peptides | |
dc.subject.fieldofresearch | Physical chemistry | |
dc.subject.fieldofresearch | Bacteriology | |
dc.subject.fieldofresearch | Medical biotechnology | |
dc.subject.fieldofresearch | Nanotechnology | |
dc.subject.fieldofresearch | Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | |
dc.subject.fieldofresearch | Biomedical engineering | |
dc.subject.fieldofresearchcode | 340407 | |
dc.subject.fieldofresearchcode | 3406 | |
dc.subject.fieldofresearchcode | 310701 | |
dc.subject.fieldofresearchcode | 3206 | |
dc.subject.fieldofresearchcode | 4018 | |
dc.subject.fieldofresearchcode | 320402 | |
dc.subject.fieldofresearchcode | 4003 | |
dc.title | Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.faculty | Office of the Snr Dep Vice Chancellor, Institute for Glycomics | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Good, Michael F. | |
gro.griffith.author | Zaman, Mehfuz | |